Neuralgia Trigeminalis

01Pathophysiology

Trigeminal neuralgia arises from demyelination of the trigeminal nerve root at its entry zone into the pons. In the classical form, the culprit is neurovascular compression, most frequently by the superior cerebellar artery (and less commonly the anterior inferior cerebellar artery or a venous structure). Chronic pulsatile contact between the vessel and the nerve damages the myelin sheath at the transition zone between central (oligodendrocyte-derived) and peripheral (Schwann cell-derived) myelin, which is the most vulnerable segment of the nerve.

This focal demyelination leads to a phenomenon called ephaptic transmission, which is abnormal cross-talk between adjacent nerve fibers. Light touch fibers (A-beta) that are normally innocuous begin to activate nociceptive (A-delta) pain fibers through short-circuit connections at the site of myelin damage. This is why a gentle stimulus such as a breeze on the cheek or light touch during tooth brushing can provoke excruciating pain. The pain is paroxysmal because the ectopic discharges fire in bursts, producing the characteristic "electric shock" quality that lasts only seconds and then abruptly stops.

In secondary trigeminal neuralgia, the demyelination is caused by a structural lesion rather than a vessel. Multiple sclerosis produces a demyelinating plaque at the root entry zone of CN V in the pons, while a cerebellopontine angle tumor (such as a meningioma, schwannoma, or epidermoid cyst) compresses the nerve externally. This distinction is critical because secondary causes tend to affect younger patients (< 40 years old), may involve the V1 (ophthalmic) division more frequently, and can produce sensory deficits between attacks, which classical trigeminal neuralgia does not.

The reason carbamazepine works as first-line treatment ties directly back to this mechanism: it stabilizes sodium channels in demyelinated axons, reducing the capacity for ectopic firing and ephaptic cross-excitation.

02Classification and Clinical Manifestation

By Division

Pain Characteristics

03Diagnostic Workup

The diagnosis of trigeminal neuralgia is primarily clinical. If the history reveals unilateral, paroxysmal, electric shock-like pain in the V2 or V3 territory, lasting seconds, provoked by innocuous facial stimuli, and the neurological exam between episodes is completely normal, the diagnosis is essentially established at the bedside. No lab test or imaging study is needed to confirm it.

However, the next best step after clinical diagnosis is MRI of the brain with and without gadolinium contrast. The purpose is not to confirm trigeminal neuralgia but to exclude secondary causes. You are looking for two things: (1) a demyelinating plaque in the pontine root entry zone suggesting multiple sclerosis, and (2) a mass lesion in the cerebellopontine angle or Meckel's cave. This step is mandatory for every newly diagnosed patient.

If MRI is normal and surgical treatment is being considered, a dedicated MRA or high-resolution MRI with CISS (constructive interference in steady state) or FIESTA sequences can be ordered to visualize the relationship between the trigeminal nerve and adjacent vessels. Identifying a compressive vascular loop preoperatively helps plan microvascular decompression.

There is no blood test that diagnoses trigeminal neuralgia. The exam will not ask you to order labs for this condition. The critical teaching point is: the best initial test is the clinical history, and the most important imaging study is MRI brain to rule out secondary pathology.

Red flags that should prompt urgent imaging:

• Age < 40 at onset

• Bilateral symptoms (think MS)

• Sensory loss or motor weakness of CN V (jaw deviation)

• V1 distribution involvement

• Progressive, non-paroxysmal pain

• Other cranial nerve deficits

04Management and Treatment

Step 1: Start carbamazepine. This is the most tested treatment fact about trigeminal neuralgia. Carbamazepine is the first-line drug and the answer to nearly every management question on this topic. Begin at 100 mg twice daily and titrate upward every 2 to 3 days as tolerated. Most patients respond at 200 to 400 mg twice daily. The mechanism of action (voltage-gated sodium channel blockade) directly addresses the ephaptic transmission at the demyelinated nerve root.

Before and during therapy, monitor for adverse effects: hyponatremia (SIADH), aplastic anemia, agranulocytosis, hepatotoxicity, and Stevens-Johnson syndrome (strongly associated with the HLA-B*1502 allele, which is prevalent in Southeast Asian populations). Obtain a baseline CBC, hepatic function panel, and serum sodium. Check HLA-B*1502 status in patients of Southeast Asian descent before initiating carbamazepine. If the allele is positive, use oxcarbazepine with caution or choose an alternative agent.

Step 2: If carbamazepine fails or is not tolerated, switch to oxcarbazepine. Oxcarbazepine has a similar mechanism and comparable efficacy with a lower incidence of hematologic toxicity and drug interactions. It still carries a risk of hyponatremia.

Step 3: If monotherapy is insufficient, add baclofen (5-10 mg three times daily, titrate to 60-80 mg/day) or lamotrigine as adjunctive therapy.

Step 4: For medically refractory disease, refer for surgery. The gold standard is microvascular decompression (MVD), also known as the Jannetta procedure. The surgeon places a Teflon pad between the offending vessel and the trigeminal nerve root, relieving chronic compression. MVD offers the best long-term outcomes and is preferred in younger, medically fit patients.

For patients who are elderly, have significant comorbidities, or refuse open craniotomy, percutaneous procedures (radiofrequency thermocoagulation, balloon compression, glycerol rhizolysis) or Gamma Knife radiosurgery are alternatives. These procedures intentionally create a controlled lesion in the trigeminal ganglion or root, trading some degree of facial numbness for pain relief.

Contraindications and cautions:

• Carbamazepine is a potent CYP3A4 inducer and reduces the efficacy of oral contraceptives, warfarin, and many other drugs.

• In pregnancy, carbamazepine is teratogenic (neural tube defects); lamotrigine or gabapentin may be considered with careful risk-benefit discussion.

• In patients with MS-related trigeminal neuralgia, MVD is not appropriate (because there is no vessel to decompress); medical therapy or ablative procedures are used instead.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most common trap with trigeminal neuralgia questions is failing to recognize the diagnosis because the vignette disguises it as a dental problem. The test-writer will describe a patient who has seen multiple dentists, had unnecessary tooth extractions, and continues to have severe facial pain. The "dental red herring" is the classic distractor. The discriminating feature is the paroxysmal, seconds-long, electric quality of the pain and the presence of a trigger zone that reliably reproduces symptoms with light touch. Dental pathology produces continuous or throbbing pain, not instantaneous shock-like paroxysms.

A second common pitfall is choosing the wrong first-line drug. Gabapentin and pregabalin are reasonable for many neuropathic pain conditions, but for trigeminal neuralgia, the answer is carbamazepine (or oxcarbazepine). If a question asks about the initial pharmacologic treatment for classic paroxysmal facial neuralgia, carbamazepine is almost always the correct choice.

Third, be alert for the young patient with bilateral trigeminal neuralgia. If the vignette describes a patient under 40 with pain on both sides of the face, the diagnosis is not idiopathic trigeminal neuralgia. The answer they are testing is multiple sclerosis as the underlying cause, and the next best step is MRI of the brain looking for demyelinating plaques.

Fourth, watch out for the question that tests the HLA-B*1502 pharmacogenomic screening step before starting carbamazepine, particularly in patients described as being of Southeast Asian, South Asian, or East Asian heritage. This is a high-yield patient safety concept.

Finally, remember that in classical trigeminal neuralgia the neurological exam is entirely normal between attacks. The moment a vignette describes facial numbness, weakness of mastication, diminished corneal reflex, or other cranial nerve deficits, you must suspect a secondary cause (tumor or demyelination) and the correct next step shifts to MRI with contrast rather than empiric carbamazepine.

The core competency being tested is the ability to (1) recognize a classic pain pattern from a well-crafted clinical vignette, (2) select the correct first-line drug, (3) know when imaging is needed to rule out a dangerous secondary etiology, and (4) identify the surgical option for refractory disease.